Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL738126 | 0.89 | HRH3 (0.55) | HRH3KCNH2MAPK14MAPTALDH1A1 | |
| SCHEMBL737105 | 0.88 | HRH3 (0.53) | HRH3KCNH2SIGMAR1MAPK14MAPT | |
| SCHEMBL737958 | 0.86 | HRH3 (0.51) | HRH3KCNH2SIGMAR1MAPTPOLB | |
| SCHEMBL737034 | 0.86 | SIGMAR1 (0.57) | HRH3KCNH2SIGMAR1ALDH1A1HRH1 | |
| SCHEMBL736599 | 0.85 | HRH3 (0.53) | HRH3KCNH2SIGMAR1HRH1 | |
| SCHEMBL738054 | 0.85 | SIGMAR1 (0.58) | HRH3KCNH2SIGMAR1ALDH1A1HRH1 | |
| SCHEMBL738221 | 0.85 | HRH3 (0.50) | HRH3KCNH2SIGMAR1MAPK14MAPT | |
| SCHEMBL736251 | 0.85 | HRH3 (0.52) | HRH3KCNH2SIGMAR1HRH1 | |
| SCHEMBL738817 | 0.84 | HRH3 (0.55) | HRH3KCNH2SIGMAR1MAPTALDH1A1 | |
| SCHEMBL736452 | 0.84 | KDM4E (0.48) | HRH3KCNH2SIGMAR1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | claimed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | claimed |
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | HRH3 2/4885KCNH2 308/4885SIGMAR1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.